This 2014 retrospective audit evaluated the safety, tolerability, and efficacy of combination phentermine and topiramate therapy for weight maintenance in 103 patients at the Austin Health Weight Control Clinic. Patients initially achieved a 10% weight loss through a very low energy diet (VLED). Among them, 61 discontinued the combination therapy,
This phase II trial evaluated the efficacy and tolerability of long-term once-weekly oral azithromycin (1500 mg) in 16 patients with histologically confirmed MALT lymphoma. Patients received the regimen for up to 6 months, with restaging at 3 and 6 months. The treatment was well tolerated, with mild nausea and diarrhea
This 2016 randomized, double-blind, placebo-controlled trial evaluated the efficacy and tolerability of melatonin (3 mg) versus amitriptyline (25 mg) and placebo in preventing migraines. Conducted over 12 weeks with 178 participants aged 18–65 experiencing 2–8 migraine attacks per month, the study found that melatonin reduced migraine days by 2.7 per
This 52-week phase 2 multicenter trial assessed the safety, tolerability, and biomarker effects of escalating doses of oral resveratrol (up to 1,000 mg twice daily) in 119 individuals with mild to moderate Alzheimer’s disease (AD). Resveratrol and its metabolites were detectable in plasma and cerebrospinal fluid (CSF), indicating central nervous
This phase I dose-escalation trial investigated the safety and tolerability of intravenous mistletoe extract (Helixor® P) in 21 patients with advanced, treatment-resistant malignancies. Doses ranged from 200 to 2000 mg weekly over a 3-week period, with a 9-week extension for high-dose patients. The maximum tolerated dose was not reached. One
This 2018 randomized, double-blind, placebo-controlled, crossover trial evaluated the effects of 6 weeks of oral nicotinamide riboside (NR) supplementation (500 mg twice daily) in 24 healthy adults aged 55–79. NR significantly increased NAD⁺ levels in peripheral blood mononuclear cells by approximately 60% compared to placebo. Exploratory analyses indicated potential reductions
This 2022 randomized, double-blind, placebo-controlled trial evaluated the safety and tolerability of nicotinamide riboside (NR) in 30 patients with clinically stable heart failure with reduced ejection fraction (HFrEF). Participants received escalating doses of NR, reaching 1,000 mg twice daily over 12 weeks. The study found that NR was safe and
This 2013 Phase I trial (Evidence-Based Complementary and Alternative Medicine, PMID: 24285980) evaluated the safety, tolerability, and immunological effects of combining mistletoe extract (Viscum album) with gemcitabine chemotherapy in 44 patients with advanced solid tumors. The combination was well tolerated up to a maximum tolerated dose of gemcitabine 1380 mg/m²
